1 / 22

RENAL AND PROSTATE DISEASE

RENAL AND PROSTATE DISEASE. Bill Lyons, M.D. UNMC Geriatrics & Gerontology. RENAL AND PROSTATE DISEASE: OBJECTIVES. Prevention and management of chronic renal disease, including ESRD Diagnosis and treatment of benign prostatic hyperplasia

mmcalister
Download Presentation

RENAL AND PROSTATE DISEASE

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. RENAL AND PROSTATE DISEASE Bill Lyons, M.D. UNMC Geriatrics & Gerontology

  2. RENAL AND PROSTATE DISEASE: OBJECTIVES • Prevention and management of chronic renal disease, including ESRD • Diagnosis and treatment of benign prostatic hyperplasia • An approach to management of prostate cancer in the elderly male

  3. CHRONIC KIDNEY DISEASE: OBJECTIVES • Why it’s important – prevalence, complications • Screening • Management to slow/prevent progression • ESRD for the non-nephrologist

  4. BACKGROUND: CKD AND ESRD • Over 372,000 in ESRD Medicare program as of end of 2000, of whom 35% age 65+ • Highest rates ESRD in older persons and African-Americans • Annual mortality rates in US for ESRD >20% • About 43% new ESRD patients have DM

  5. RISKS OF CHRONIC KIDNEY DISEASE • Hospitalization (3x vs. general population) • All-cause mortality • Cardiovascular mortality, especially • Increasing proteinuria • Decreasing GFR • CKD underdiagnosed, undertreated

  6. PROGRESSION AMONG DIABETICS • Microalbuminuria  overt proteinuria  renal insufficiency  ESRD • Established nephropathy in majority of diabetics progresses up to 10 mL/min per year • Demographics: get ready

  7. PROGRESSION AMONG DIABETICS, cont. • Risk factors for development and progression: • Degree, duration of glycemic control • Hypertension • Male sex • Higher total cholesterol • Smoking

  8. SCREENING FOR CKD • Healthy (nondiabetic)? No commonly accepted screening guidelines • Diabetics • Screen for microalbuminuria • Early morning spot urine sample • Urine alb/Cr ratio > 30 mg/g is abnormal • Stand to benefit from agents that decrease intraglomerular pressure

  9. MANAGEMENT PRINCIPLES • Start treatment early in CKD to slow or prevent progression to kidney failure • Regardless of cause of CKD, hypertension increases risk of adverse outcomes: • Progression of kidney failure to ESRD • Cardiovascular disease • Premature death

  10. MANAGEMENT PRINCIPLES, cont. • For some elders with CKD, makes sense to prevent/treat complications of CKD and comorbidities; worry less about progression to ESRD. • Avoid renal insults: • IV contrast • Nephrotoxic drugs • Hypotension

  11. MANAGEMENT OF CKD • In diabetic patients, intensive control of blood glucose can slow or prevent progression of CKD (at least in early stages). • Good control of BP probably most important intervention in slowing progression • Goal <130/80 for CKD or DM • Perhaps modify if orthostatic signs/symptoms

  12. MANAGEMENT OF CKD, cont. • ACEi and ARB slow progression to ESRD better than other antihypertensives • Start in diabetics with microalbuminuria or proteinuria, even if BP within goal • Monitor renal function and potassium closely after starting these drugs • Renovascular disease common; risk of ARF • Don’t mix with NSAID

  13. MANAGEMENT OF CKD, cont. • Restrict protein in diet? • Evidence from clinical trials mixed • No recommendation for/against

  14. BONE AND MINERAL DISEASE IN ADVANCED CKD • Worse kidney function  phosphate retention  hypocalcemia and low calcitriol  secondary hyperparathyroidism • Metabolic acidosis also  bone disease • Management: • Modify diet (refer to Nutritionist) • Phosphate binders • Calcitriol • NaHCO3 650-1300 mg bid-tid • Nephrology referral

  15. ADVANCED CKD MANAGEMENT • Serially monitor calcium, phosphorus, PTH to determine whether bicarb or calcitriol should be dose-adjusted. • Consider low-dose ASA • Epoetin alfa (perhaps with IV iron) to maintain Hct in range 33-36%

  16. END-STAGE RENAL DISEASE • Start discussing need for RRT at least 6-12 months before anticipated date • When initiate dialysis? • Classic: severe hyperkalemia, acidosis, refractory volume overload, encephalopathy, bleeding diathesis, serositis (pericarditis) • Consider also: severe fatigue, pruritus, cognitive impairment, weight loss

  17. ESRD, cont. • If RRT not chosen, • Consider dietary protein restriction • Diuretics, nitrates, opiates • Antiemetics • HD vs. PD? • Patient preference probably paramount • PD more challenging in setting of cognitive problems, poor vision, physical disabilities

  18. HEMODIALYSIS • Plan for AVF when CrCl below 25 or when anticipate ESRD within one year • Fistula should be in place for several months before time of need to allow for arterialization • Major complications: • Vascular access: thrombosis, infection • Other: arrhythmia, sudden death, hemodynamic instability, anticoag problems

  19. CANCER SCREEN IN ESRD? • Chertow: ?Benefit in finding early occult cancer in patient with 3-4 year life expectancy • Probably better to focus on • Optimizing dialysis • Primary and secondary prevention of cardiovascular disease

  20. REFERENCES AND READINGS • Levey AS, Mulrow CD. Ann Intern Med 2005;143:79-81. • Chertow GM. JAMA 2004;291(10):1252-1259. • Kausz AT. Clinical Geriatrics 2004;12(7):39-46.

  21. Post-test question one • All of the following statements regarding chronic kidney disease are true EXCEPT: (a) Lower values of glomerular filtration rate correlate with increased risk of cardiovascular mortality. (b) Smoking is a risk factor for the progression of kidney disease among diabetics. (c) Patients aged 65 and older should be routinely screened for chronic kidney disease with a spot early morning urine test for microalbuminuria. (d) The blood pressure for patients with chronic kidney disease should be maintained below 130/80 using antihypertensive therapy. (e) Patients with advanced chronic kidney disease may benefit from erythropoietin, dosed to maintain hematocrit between 33 and 36%.

  22. Correct Answer:    (c) Patients aged 65 and older should be routinely screened for chronic kidney disease with a spot early morning urine test for microalbuminuria. Feedback:(c).Answers (a), (b), (d), and (e) are all correct statements, based on the material covered in this module. Answer (c) is not a true statement, as there is not a consensus that all patients > aged 65 and older or otherwise should undergo screening for proteinuria. Diabetic patients are another matter. They should indeed be screened for microalbuminuria, using an early morning spot urine test.

More Related